

Supporting Information

Atroposelective Synthesis of N-N Axially Chiral Pyrrolylamides by Combined-acid Catalytic Paal-Knorr Reaction

Zhihuang Chen, Qi Chen, Guogang Tu, Xiaodong Xiong*

School of Pharmacy, Nanchang University, Nanchang 330006, Jiangxi, China

E-mail: xiongd@ncu.edu.cn

Table of contents

S2–S11	Experimental procedures
S11–S47	Physical data
S48	References
S49–S87	¹H and ¹³C NMR Spectra

(A) General information

Commercially available reagents were used directly without further purification. For others, we prepared them in suitable reaction conditions. NMR spectra were recorded on a Bruker ADVANCE III 400MHz spectrometer (^1H NMR: 400 MHz, ^{13}C NMR: 100 MHz). Chemical shifts (δ) were reported in ppm relative to CDCl_3 (δ 7.26) for the ^1H NMR and to CDCl_3 (δ 77.16) for the ^{13}C NMR measurements. Mass spectra were recorded on Thermo Finnigan MAT 95 XL spectrometer and Bruker solariX 9.4 Tesla FTICR spectrometer. GC/MS analysis was conducted on a Shimadzu GCMSQP2010 instrument equipped with a Restec-5HT column (30 m \times 0.25 mm, Hewlett-Packard). IR spectra were recorded on a PerkinElmer FT-IR spectrophotometer and reported in terms of wavenumber of absorption (cm^{-1}). Flash column chromatography was performed on 300-400 mesh silica gel from Qingdao Haiyang Chemical Co., Ltd. Reactions were monitored by thin-layer chromatography (TLC) using 254 nm UV light to visualize the progress of the reactions.


(B) General procedure for the synthesis of the substrate

Typical procedure for the synthesis of hydrazines 1

Substrates **1** could be conveniently synthesized according to the known literature procedures.^{1,2} Their ¹H NMR spectroscopic and physical data were compared with reporting data, ensuring correct structures.


Typical procedure for the synthesis of 1,4-diketones 2

Substrates **2** could be synthesized according to the known literature procedures.³ Their ¹H NMR spectroscopic and physical data were compared with reporting data, ensuring correct structures.



General procedure:


To a solution of sodium hydride (60% dispersion in mineral oil) (400 mg, 11 mmol) in anhydrous THF (20 mL) was slowly added the solution of methyl acetoacetate **B** (1.16 g, 10 mmol) in THF (10 mL) at 0 °C. The reaction mixture was stirred at 0 °C for 0.5 h. Then, a solution of 2-bromo-1-phenylethan-1-one **A** (10 mmol) in THF (5 mL) was added to the mixture, which was stirred at room temperature for another 12 h. After the completion of the reaction which was indicated by TLC, the reaction mixture was quenched with H₂O and the aqueous layer was extracted with EtOAc (3×30 mL). The combined organic layers were dried over anhydrous Na₂SO₄ and then concentrated under reduced pressure. Then the crude product was purified by silica gel column chromatography to give 1,4-diketones **2**

(C) Table S1. Optimization of reaction conditions^a

entry	CPA	solvent	Lewis acid	T (°C)	additive	yield (%)	ee (%) ^b
1	-	toluene	Fe(OTf) ₃	25	4Å MS	70	0
2	C1	toluene	-	25	4Å MS	80	-1
3	C1	toluene	Fe(OTf) ₃	25	4Å MS	90	-6
4	C2	toluene	Fe(OTf) ₃	25	4Å MS	92	-53
5	C3	toluene	Fe(OTf) ₃	25	4Å MS	93	-65
6	C4	toluene	Fe(OTf) ₃	25	4Å MS	60	-46
7	C5	toluene	Fe(OTf) ₃	25	4Å MS	70	-50
8	C6	toluene	Fe(OTf) ₃	25	4Å MS	92	53
9	C7	toluene	Fe(OTf) ₃	25	4Å MS	90	85
10	C8	toluene	Fe(OTf) ₃	25	4Å MS	94	87
11	C8	toluene	Fe(OTf) ₃	25	5Å MS	70	73
12	C8	toluene	Fe(OTf) ₃	25	3Å MS	90	60
13	C8	toluene	Fe(OTf) ₃	25	MgSO ₄	92	79
14	C8	toluene	Fe(OTf) ₃	25	Na ₂ SO ₄	88	72
15	C8	toluene	Fe(OTf) ₃	25	-	82	76
16	C8	CHCl ₃	Fe(OTf) ₃	25	4Å MS	10	2
17	C8	CH ₂ Cl ₂	Fe(OTf) ₃	25	4Å MS	30	40
18	C8	CCl ₄	Fe(OTf) ₃	25	4Å MS	85	72
19	C8	hexane	Fe(OTf) ₃	25	4Å MS	88	70
20	C8	toluene	Fe(OTf) ₃	0	4Å MS	96	93
21	C8	toluene	Fe(OTf) ₃	-20	4Å MS	94	92
22	C8	toluene	FeCl ₃	0	4Å MS	85	20
23	C8	toluene	Cu(OTf) ₂	0	4Å MS	70	30
24	C8	toluene	In(OTf) ₃	0	4Å MS	86	35
25	C8	toluene	Sc(OTf) ₃	0	4Å MS	92	87
26	C8	toluene	Bi(OTf) ₃	0	4Å MS	94	77
27	C8	toluene	-	0	4Å MS	82	24


^a Reaction conditions: **1a** (0.0375 mmol), **2a** (0.025 mmol), catalyst (10 mol%), Lewis acid (10 mol%), additivity (20 mg), solvent (1.0 mL) at given temperature for 8 h. ^b Determined by HPLC analysis.

(D) General procedure for the asymmetric synthesis of axially chiral N-N amide-pyrrole 3




Hydrazide **1** (0.075 mmol, 1.5 eq) was added to a solution of 1,4-diketones **2** (0.05 mmol, 1.0 eq), **C8** (10 mol%), $\text{Fe}(\text{OTf})_3$ (10 mol%), and 4 Å MS (40 mg) in toluene (2.0 mL) at 0 °C. The reaction was stirred for 8 h until the 1,4-diketones **2** was fully consumed (monitored by TLC), then the mixture was concentrated under reduced pressure and purified by flash chromatography eluted with PE/EA to afford the corresponding axially chiral N-N amide-pyrroles product **3**.

(E) General procedure for gram-scale reaction




Hydrazide **1a** (3 mmol, 1.5 eq) was added to a solution of 1,4-diketones **2a** (2 mmol, 1.0 eq), **C8** (10 mol%), $\text{Fe}(\text{OTf})_3$ (10 mol%), and 4 Å MS (1.2 g) in toluene (60 mL) at 0 °C. The reaction was stirred for 8 h until the 1,4-diketones **2** was fully consumed (monitored by TLC), then the mixture was concentrated under reduced pressure and purified by flash chromatography eluted with PE/EA to afford the corresponding axially chiral N-N amide-pyrrole product **3a** (687.4 mg, 96% yield, 91% ee).

(F) Synthetic transformations




To a dry round-bottom flask equipped with a magnetic stir bar, **3a** (35.8 mg, 0.1 mmol) was dissolved in DMF (2 mL). Then FeCl_3 (10 mol%) and NIS (1.2 eq) were added to


the mixture at 25 °C. After the completion of the reaction which was indicated by TLC, H₂O (5 mL) was added and the mixture was extracted with EtOAc (3×10 mL). The combined organic layers were washed with brine, dried with Na₂SO₄ and concentrated under reduced pressure. Further purification by flash column chromatography on silica gel to provide product **4** (45.5 mg, 94% yield, 93% ee).




To a dry round-bottom flask equipped with a magnetic stir bar, **3a** (35.8 mg, 0.1 mmol) was dissolved in THF (4 mL) and H₂O (0.4 mL) at 25 °C. Then ceric ammonium nitrate (CAN) (274 mg, 0.5 mmol) was added in small portions to the mixture. After the completion of the reaction which was indicated by TLC, H₂O (10 mL) was added and the mixture was extracted with EtOAc (3×10 mL). The combined organic layers were washed with brine, dried with Na₂SO₄ and concentrated under reduced pressure. Further purification by flash column chromatography on silica gel to provide product **5** (31.6 mg, 85% yield, 90% ee).




To a dry round-bottom flask equipped with a magnetic stir bar, **3a** (35.8 mg, 0.1 mmol) was dissolved in MeOH (1 mL) and H₂O (1 mL). Then LiOH (10 eq) was added to the mixture, and the reaction was stirred at 60 °C. After the completion of the reaction which was indicated by TLC, H₂O (5 mL) was added and the mixture was extracted with EtOAc (3×10 mL). The combined organic layers were washed with brine, dried with Na₂SO₄ and concentrated under reduced pressure. Further purification by flash column chromatography on silica gel to provide product **6** (27.5 mg, 80% yield, 90% ee).



Under Ar atmosphere, to a dry round-bottom flask equipped with a magnetic stir bar, **4** (48.4 mg, 0.1 mmol), $\text{PdCl}_2(\text{dppf})$ (7.4 mg, 0.01 mmol), Cs_2CO_3 (65.2 mg, 0.2 mmol), boronic acid (18.3 mg, 0.15 mmol) was added in THF (3 mL). Then the reaction mixture was stirred at 55 °C for 3 h. After cooling to room temperature, H_2O (5 mL) was added. The suspension was filtered through a pad of Celite washing with ethyl acetate (5 mL) and filtrate was extracted with EtOAc (3×10 mL). The combined organic layers were washed with brine, dried with Na_2SO_4 and concentrated under reduced pressure. The residual crude product was chromatographed on silica gel to give the product **7** (31.6 mg, 90% yield, 92% ee).




Under Ar atmosphere, to a dry round-bottom flask equipped with a magnetic stir bar, **4** (48.4 mg, 0.1 mmol), Pd(OAc)_2 (0.48 mg, 0.002 mmol), CuI (0.38 mg, 0.002 mmol), Xantphos (1.16 mg, 0.002 mmol), Cs_2CO_3 (65.2 mg, 0.2 mmol), ethynylbenzene (15.3 mg, 0.15 mmol) was added in DMF (3 mL). Then the reaction mixture was stirred at 60 °C for 3 h. After cooling to room temperature, H_2O (10 mL) was added. The suspension was filtered through a pad of celite, washing and then extracted with EtOAc (3×10 mL). The combined organic layers were washed with brine, dried with Na_2SO_4 and concentrated under reduced pressure. The residual crude product was chromatographed on silica gel to give the product **8** (38.9 mg, 85% yield, 91% ee).



Under Ar atmosphere, to a dry round-bottom flask equipped with a magnetic stir bar, **4** (48.4 mg, 0.1 mmol), PdCl₂(dppf) (7.4 mg, 0.01 mmol), Cs₂CO₃ (65.2 mg, 0.2 mmol), isopropenylboronica acid pinacol ester (33.6 mg, 0.2 mmol) was added in THF (3 mL). Then the reaction mixture was stirred at 50°C for 2 h. After cooling to room temperature, H₂O (5 mL) was added. The suspension was filtered through a pad of celite, washing and then extracted with EtOAc (3×10 mL). The combined organic layers were washed with brine, dried with Na₂SO₄ and concentrated under reduced pressure. The residual crude product was chromatographed on silica gel to give the product **9** (32.6 mg, 82% yield, 90% ee).

(G) Unsuccessful examples



(H) Mechanistic studies

To a flame-dried Schlenk tube was added **C8** (0.01 mmol) and Fe(OTf)₃ (0.01 mmol) and CDCl₃ (0.5 mL). After 30 min stirring at rt, the solution was transferred to a NMR tube and the ³¹P NMR was taken, a new peak was transferred from -9.0 ppm to -9.4 ppm.




Fig. 1 ^{31}P NMR spectra of **C8** and binary-acid **C8/Fe(OTf)₃**

To a flame-dried Schlenk tube was added **C8** (0.01 mmol), $\text{Fe}(\text{OTf})_3$ (0.01 mmol), and CH_2Cl_2 (0.5 mL). After 30 min stirring at rt, an aliquot was diluted with CH_3CN ($\text{CH}_3\text{CN}:\text{CH}_2\text{Cl}_2 = 5:1$) and subjected to analysis by ESI-MS.




Fig. 2 ESI-MS of binary-acid **C8/Fe(OTf)₃**

To a flame-dried Schlenk tube was added **C8** (0.01 mmol), Fe(OTf)₃ (0.01 mmol), and CH₂Cl₂ (0.5 mL). After 30 min stirring at rt, **1a** (0.01 mmol) and **2a** (0.01 mmol) were added, then stirred for another 30 min, an aliquot was diluted with CH₃CN (CH₃CN:CH₂Cl₂ = 5:1) and subjected to analysis by ESI-MS.





Fig. 3 ESI-MS of binary-acid **C8**/Fe(OTf)₃ catalyzed the Paal-Knorr reaction of **1a** and **2a**


The amount of Fe(OTf)₃ was investigated for the enantioselectivity of the Paal-Knorr reaction



entry	x	y	yield (%)	ee (%)
1	10	0	82	24
2	10	2.5	89	32
3	10	5	92	75
4	10	10	96	93
5	10	20	97	90
6	10	40	96	86
7	5	5	91	85


^aReactions were carried out with **1a** (0.075 mmol), **2a** (0.05 mmol), **C8** (x mol%), Fe(OTf)₃ (y mmol%), and 4 Å MS (40 mg) in toluene (2 mL) at 0 °C.

(I) Analytical Data



methyl 2-(2-(3-methylphenyl)-2-oxoethyl)-3-oxopentanoate (2j)

¹H NMR (400 MHz, CDCl₃) δ 2.21-2.43 (m, 6H), 3.43 (m, 1H), 3.54-3.75 (m, 4H), 4.14 (m, 1H), 7.27 (m, 2H), 7.68 (d, *J* = 7.6, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 202.4, 197.2, 169.5, 138.5, 136.0, 134.3, 128.7, 128.6, 125.4, 53.6, 52.7, 37.5, 30.3, 21.3. HRMS (ESI) calcd for C₁₄H₁₆O₄ *m/z* [M+H]⁺: 249.1121, found: 249.1123.




methyl 2-(2-(3-bromophenyl)-2-oxoethyl)-3-oxopentanoate (2w)

¹H NMR (400 MHz, CDCl₃) δ 1.11 (m, 3H), 2.79 (m, 2H), 3.39-3.59 (m, 1H), 3.61-3.86 (m, 4H), 4.12-4.27 (m, 1H), 7.35 (m, 1H), 7.70 (d, *J* = 8.0, 1H), 7.90 (d, *J* = 7.9, 1H), 8.09 (d, *J* = 2.1, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 205.0, 196.1, 169.5, 137.9, 136.5, 131.4, 130.4, 126.8, 123.2, 52.9, 52.8, 37.7, 36.5, 7.8. HRMS (ESI) calcd for C₁₄H₁₅BrO₄ *m/z* [M+H]⁺: 327.0226, found: 327.0222.


CPA catalysts

All chiral phosphoric acid catalysts are commercially available (C1-C7). Catalyst C8 had synthesized according to the known literature procedures.⁴

Chiral phosphoric acid C8




¹H NMR (400 MHz, CDCl₃) δ 1.98 (s, 6H), 2.05 (s, 8H), 2.18 (s, 6H), 2.28 (s, 8H), 2.82 (m, 2H), 2.96 (m, 2H), 6.48 (s, 1H), 6.73 (s, 4H), 6.82 (s, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 142.9, 142.9, 141.2, 139.3, 139.3, 136.8, 136.4, 136.3, 133.6, 132.5, 132.5, 132.1, 132.1, 130.8, 128.6, 127.4, 60.4, 38.3, 28.9, 21.3, 21.0, 20.4, 18.5. ³¹P NMR (162 MHz, CDCl₃) δ -8.90. HRMS (ESI) calcd for C₃₇H₃₉O₄P *m/z* [M+H]⁺: 579.2658, found: 579.2654.




(*R*)-methyl 1-((tert-butoxycarbonyl)(methyl)amino)-2-methyl-5-(*p*-tolyl)-1H-pyrrole-3-carboxylate (3a)


Colorless oil. $[\alpha]_D^{25} = -67.9$ (*c* 0.44, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 1.35 (s, 6H), 1.54 (s, 3H), 2.36 (s, 3H), 2.45 (s, 3H), 2.97 (s, 1H), 3.09 (s, 2H), 3.81 (s, 1H), 3.83 (s, 2H), 6.57-6.59 (m, 1H), 7.17-7.19 (m, 2H), 7.24-7.28 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 165.8, 165.7, 154.4, 154.2, 137.6, 137.5, 137.1, 136.9, 132.1, 129.5, 129.3, 128.4, 128.3, 128.0, 127.4, 110.6, 110.4, 107.6, 107.2, 82.5, 82.3, 51.1, 51.0, 38.7, 37.5, 28.3, 28.2, 21.4, 21.3, 10.6, 10.5. HRMS (ESI) calcd for C₂₀H₂₆N₂O₄ *m/z* [M+H]⁺: 359.1965, found: 359.1956. Enantiomeric excess was found to be 93% by chiral HPLC (ChiralPak OD column, hexane/*i*-PrOH = 90:10, 1.0 ml/min, *t*_{major} = 4.9 min, *t*_{minor} = 4.3 min).



RT [min]	Type	Width [min]	Area	Height	Area%
4.317	MM m	0.56	11938.59	1257.02	49.71
4.937	MM m	0.83	12077.67	716.53	50.29




RT [min]	Type	Width [min]	Area	Height	Area%
4.325	MM m	0.43	442.46	33.03	3.50
4.972	MM m	1.40	12214.41	549.68	96.50




(R)-methyl 1-((tert-butoxycarbonyl)(methyl)amino)-2-methyl-5-phenyl-1H-pyrrole-3-carboxylate(3b)


Yellow oil. $[\alpha]_D^{25} = -55.8$ (*c* 0.25, CHCl_3); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 1.34 (s, 6H), 1.53 (s, 3H), 2.46 (s, 3H), 2.98 (s, 1H), 3.12 (s, 2H), 3.81 (s, 1H), 3.84 (s, 2H), 6.61-6.63 (m, 1H), 7.30-7.40 (m, 5H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 165.7, 165.6, 154.4, 154.2, 137.3, 137.2, 132.0, 131.3, 131.2, 128.8, 128.6, 128.1, 127.2, 127.5, 110.8, 110.5, 108.0, 107.6, 82.5, 82.4, 51.2, 51.1, 38.7, 37.6, 28.3, 28.1, 10.6, 10.5. HRMS (ESI) calcd for $\text{C}_{19}\text{H}_{24}\text{N}_2\text{O}_4$ m/z $[\text{M}+\text{H}]^+$: 345.1809, found: 345.1807. Enantiomeric excess was found to be 91% by chiral HPLC (ChiralPak OD column, hexane/*i*-PrOH = 99:1, 1.0 ml/min, $t_{\text{major}} = 18.7$ min, $t_{\text{minor}} = 14.3$ min).



RT [min]	Type	Width [min]	Area	Height	Area%
14.264	MM m	3.07	8503.22	138.88	49.98
18.510	MM m	6.89	8511.19	57.34	50.02




RT [min]	Type	Width [min]	Area	Height	Area%
14.684	MM m	2.28	267.72	4.49	4.45
18.699	MM m	8.29	5748.87	37.80	95.55




(R)-methyl 1-((tert-butoxycarbonyl)(methyl)amino)-5-(4-methoxyphenyl)-2-methyl-1H-pyrrole-3-carboxylate (3c)


Yellow oil. $[\alpha]_D^{25} = -65.7$ (*c* 0.51, CHCl_3); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 1.36 (s, 6H), 1.52 (s, 3H), 2.44 (s, 3H), 2.96 (s, 1H), 3.09 (m, 3H), 3.80 (s, 1H), 3.83 (s, 5H), 6.53-6.54 (m, 1H), 6.88-6.91 (m, 2H), 7.26-7.31 (m, 2H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 165.8, 165.7, 159.4, 159.3, 154.4, 154.3, 136.8, 136.6, 131.9, 129.7, 129.0, 123.8, 123.7, 114.2, 114.0, 110.5, 110.3, 107.3, 106.8, 82.5, 82.3, 55.5, 55.4, 51.1, 51.0, 38.7, 37.5, 28.6, 28.3, 28.2, 10.6, 10.5. HRMS (ESI) calcd for $\text{C}_{20}\text{H}_{26}\text{N}_2\text{O}_5$ m/z $[\text{M}+\text{H}]^+$: 375.1914, found: 375.1905. Enantiomeric excess was found to be 90% by chiral HPLC (ChiralPak OD column, hexane/*i*-PrOH = 99:1, 1.0 ml/min, $t_{\text{major}} = 28.3$ min, $t_{\text{minor}} = 13.8$ min).



RT [min]	Type	Width [min]	Area	Height	Area%
13.925	BM m	3.71	4560.17	91.44	50.01
29.229	MM m	14.34	4557.44	19.05	49.99




RT [min]	Type	Width [min]	Area	Height	Area%
13.845	MM m	1.85	452.61	9.65	4.91
28.339	BB	13.06	8772.80	37.32	95.09




(R)-methyl 1-((tert-butoxycarbonyl)(methyl)amino)-5-(4-fluorophenyl)-2-methyl-1H-pyrrole-3-carboxylate (3d)

Pale yellow oil. $[\alpha]_D^{25} = -69.2$ (c 0.09, CHCl_3); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 1.35 (s, 6H), 1.53 (s, 3H), 2.45 (s, 3H), 2.98 (s, 1H), 3.10 (m, 2H), 3.81 (s, 1H), 3.83 (s, 2H), 6.57-6.58 (m, 1H), 7.03-7.09 (m, 2H), 7.30-7.37 (m, 2H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 165.6, 165.6, 163.8, 163.7, 161.3, 161.2, 154.4, 154.1, 137.2, 137.0, 131.1 (2), 130.1, 130.0, 129.4 (2), 127.4 (3), 127.3, 115.9, 115.7, 115.5, 110.8, 110.5, 108.0, 107.6, 82.7, 82.5, 51.2, 51.1, 38.8, 37.6, 28.3, 28.2, 10.6, 10.5. HRMS (ESI) calcd for $\text{C}_{19}\text{H}_{23}\text{FN}_2\text{O}_4$ m/z $[\text{M}+\text{H}]^+$: 363.1715, found: 363.1710. Enantiomeric excess was found to be 92% by chiral HPLC (ChiralPak OD column, hexane/*i*-PrOH = 99:1, 1.0 ml/min, $t_{\text{major}} = 13.1$


min, $t_{\text{minor}} = 8.7$ min).



RT [min]	Type	Width [min]	Area	Height	Area%
8,648	BB	1,98	7547,00	281,32	50,06
13,554	MM m	3,44	7528,78	112,54	49,94




RT [min]	Type	Width [min]	Area	Height	Area%
8,728	MM m	0,92	863,82	35,70	4,00
13,123	BM m	3,97	20746,60	306,70	96,00




(*R*)-methyl 1-((tert-butoxycarbonyl)(methyl)amino)-5-(4-chlorophenyl)-2-methyl-1H-pyrrole-3-carboxylate (3e)

Colorless oil. $[\alpha]_D^{25} = -56.8$ (c 0.17, CHCl_3); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 1.35 (s, 6H), 1.53 (s, 3H), 2.45 (s, 3H), 2.98 (s, 1H), 3.10 (m, 2H), 3.81 (s, 1H), 3.83 (s, 2H), 6.62 (d, $J = 8.4$, 1H), 7.26-7.36 (m, 4H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 165.5 (2), 154.4, 154.1, 137.6, 137.4, 133.7 (2), 130.9, 130.8, 129.7, 129.6, 129.3, 129.1, 128.9, 128.6, 111.0, 110.7, 108.4, 108.0, 82.8, 82.6, 51.2, 51.1, 38.8, 37.6, 28.3, 28.2, 10.6, 10.5. HRMS (ESI) calcd for $\text{C}_{19}\text{H}_{23}\text{ClN}_2\text{O}_4$ m/z $[\text{M}+\text{H}]^+$: 379.1419, found: 379.1417. Enantiomeric excess was found to be 93% by chiral HPLC (ChiralPak OD column,


hexane/*i*-PrOH = 90:10, 1.0 ml/min, $t_{\text{major}} = 5.4$ min, $t_{\text{minor}} = 4.4$ min).



RT [min]	Type	Width [min]	Area	Height	Area%
4.426	BV	1.05	7082.92	762.39	49.97
5.486	VV	1.32	7090.49	440.81	50.03




RT [min]	Type	Width [min]	Area	Height	Area%
4.418	MM m	0.25	286.76	39.85	3.44
5.443	BV	1.46	8050.79	533.72	96.56




(*R*)-methyl 5-(4-bromophenyl)-1-((tert-butoxycarbonyl)(methyl)amino)-2-methyl-1H-pyrrole-3-carboxylate (3f)

Yellow oil. $[\alpha]_D^{25} = -80.7$ (c 0.73, CHCl_3); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 1.35 (s, 6H), 1.54 (s, 3H), 2.45 (s, 3H), 2.99 (s, 1H), 3.11 (m, 2H), 3.81 (s, 1H), 3.83 (s, 2H), 6.63 (d, $J = 8.4$, 1H), 7.24 (t, $J = 8.4$, 2H), 7.50 (t, $J = 7.2$, 2H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 165.5 (2), 154.4, 154.1, 137.6, 137.5, 132.0, 131.8, 130.8 (2), 130.2, 130.1, 129.6, 128.8, 121.9, 121.8, 111.0, 110.7, 108.4, 108.0, 82.8, 82.6, 51.2, 51.1, 38.8, 37.6, 28.3, 28.2, 10.6, 10.5. HRMS (ESI) calcd for $\text{C}_{19}\text{H}_{23}\text{BrN}_2\text{O}_4$ m/z $[\text{M}+\text{H}]^+$: 423.0914, found:


423.0914. Enantiomeric excess was found to be 92% by chiral HPLC (ChiralPak OD column, hexane/*i*-PrOH = 95:5, 1.0 ml/min, $t_{\text{major}} = 6.9$ min, $t_{\text{minor}} = 5.1$ min).



RT [min]	Type	Width [min]	Area	Height	Area%
5.204	VV	0.62	9836.14	867.35	50.10
7.174	VB	1.70	9796.54	374.86	49.90




RT [min]	Type	Width [min]	Area	Height	Area%
5.119	MM m	0.39	240.50	24.65	3.98
6.933	BM m	2.27	5805.49	246.15	96.02




(*R*)-methyl 1-((tert-butoxycarbonyl)(methyl)amino)-5-(4-iodophenyl)-2-methyl-1H-pyrrole-3-carboxylate (3g)

Yellow oil. $[\alpha]_D^{25} = -81.2$ (c 0.79, CHCl_3); ^1H NMR (400 MHz, CDCl_3) δ 1.35 (s, 6H), 1.54 (s, 3H), 2.44 (s, 3H), 2.90-3.19 (m, 3H), 3.78-3.91 (m, 3H), 6.63 (d, $J=9.1$, 1H), 7.01-7.17 (m, 2H), 7.70 (d, $J=7.5$, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 165.5, 154.0, 138.0, 137.8, 137.6, 130.8, 130.6, 129.7, 128.9, 110.8, 108.4, 108.0, 93.2, 82.8, 82.6, 51.2, 51.1, 38.8, 37.6, 28.3, 28.2, 10.6. HRMS (ESI) calcd for $\text{C}_{19}\text{H}_{23}\text{IN}_2\text{O}_4$ m/z $[\text{M}+\text{H}]^+$:


471.0775, found: 471.0766. Enantiomeric excess was found to be 93% by chiral HPLC (ChiralPak OD column, hexane/*i*-PrOH = 95:5, 1.0 ml/min, $t_{\text{major}} = 7.2$ min, $t_{\text{minor}} = 5.2$ min).



RT [min]	Type	Width [min]	Area	Height	Area%
5.204	VV	0.62	9836.14	867.35	50.10
7.174	VB	1.70	9796.54	374.86	49.90




RT [min]	Type	Width [min]	Area	Height	Area%
5.215	MM m	0.34	421.91	46.15	3.47
7.151	BB	2.49	11734.37	441.76	96.53




(*R*)-methyl 1-((tert-butoxycarbonyl)(methyl)amino)-5-(4-cyanophenyl)-2-methyl-1H-pyrrole-3-carboxylate (3h)

Yellow oil. $[\alpha]_D^{25} = -117.1$ (c 0.67, CHCl_3); ^1H NMR (400 MHz, CDCl_3) δ 1.33 (s, 6H), 1.54 (s, 3H), 2.46 (d, $J = 1.9$, 3H), 3.10 (d, $J = 50.5$, 3H), 3.83 (d, $J = 9.4$, 3H), 6.77 (d, $J = 15.6$, 1H), 7.48 (t, $J = 6.8$, 2H), 7.65 (t, $J = 7.0$, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 165.2, 153.9, 138.8, 135.4, 132.7, 132.6, 129.8, 127.7, 127.0, 118.8, 111.4, 110.8,


110.0, 109.8, 83.2, 82.9, 51.3, 51.3, 38.9, 37.7, 28.3, 28.1, 10.6, 10.6.. HRMS (ESI) calcd for C₂₀H₂₃N₃O₄ *m/z* [M+Na]⁺: 392.1581, found: 392.1590. Enantiomeric excess was found to be 94% by chiral HPLC (ChiralPak OD column, hexane/*i*-PrOH = 95:5, 1.0 ml/min, *t*_{major} = 19.8 min, *t*_{minor} = 11.0 min).



RT [min]	Type	Width [min]	Area	Height	Area%
11.037	MM m	1.91	1399.22	47.88	50.19
19.973	MM m	4.53	1388.62	20.38	49.81




RT [min]	Type	Width [min]	Area	Height	Area%
11.013	MM m	1.03	49.92	2.10	2.91
19.780	BB	4.54	1665.90	24.31	97.09




(*R*)-methyl 1-((tert-butoxycarbonyl)(methyl)amino)-2-methyl-5-(4-nitrophenyl)-1H-pyrrole-3-carboxylate (3i)

Brown solid. $[\alpha]_D^{25} = -43.5$ (*c* 0.7, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 1.34 (s, 6H), 1.56 (s, 3H), 2.47 (s, 3H), 3.12 (d, *J* = 48.2, 3H), 3.84 (d, *J* = 9.2, 3H), 6.84 (d, *J* = 14.4, 1H), 7.53 (d, *J* = 7.8, 2H), 8.23 (t, *J* = 7.7, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 165.1, 153.8, 146.6, 139.2, 137.3, 129.5, 127.6, 126.9, 124.4, 124.2, 111.6, 110.6, 110.4, 83.3,


83.0, 51.4, 51.3, 38.9, 37.7, 28.3, 28.1, 10.6, 10.6. HRMS (ESI) calcd for C₁₉H₂₄N₃O₆ m/z [M+H]⁺: 390.1660, found: 390.1664. Enantiomeric excess was found to be 92% by chiral HPLC (ChiralPak OD column, hexane/*i*-PrOH = 80:20, 1.0 ml/min, t_{major} = 10.2 min, t_{minor} = 6.0 min).



RT [min]	Type	Width [min]	Area	Height	Area%
6.089	BM m	1.57	5393.36	292.19	49.60
10.486	MM m	2.36	5479.61	138.78	50.40




RT [min]	Type	Width [min]	Area	Height	Area%
5.990	MM m	0.64	246.56	18.81	3.96
10.196	MM m	2.44	5976.39	180.18	96.04




(*R*)-methyl 1-((tert-butoxycarbonyl)(methyl)amino)-2-methyl-5-(*m*-tolyl)-1H-pyrrole-3-carboxylate (3j)

Yellow oil. $[\alpha]_D^{25} = -54.2$ (*c* 0.25, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 1.37 (s, 6H), 1.54 (s, 3H), 2.40 (d, *J* = 39.1, 6H), 3.03 (d, *J* = 44.8, 3H), 3.82 (d, *J* = 8.9, 3H), 6.60 (d, *J* = 4.8, 1H), 7.08-7.27 (m, 4H); ¹³C NMR (100 MHz, CDCl₃) δ 165.7, 154.2, 138.3, 137.1, 132.1, 131.1, 128.8, 128.7, 128.5, 128.3, 125.1, 124.6, 110.4, 107.9, 107.5, 82.3,


51.1, 51.1, 38.7, 37.5, 28.3, 28.2, 21.6, 10.5, 10.5. HRMS (ESI) calcd for C₂₀H₂₆N₂O₄ *m/z* [M+H]⁺: 359.1965, found: 359.1963. Enantiomeric excess was found to be 91% by chiral HPLC (ChiralPak OD column, hexane/*i*-PrOH = 99:1, 1.0 ml/min, *t*_{major} = 16.1 min, *t*_{minor} = 13.1 min).



RT [min]	Type	Width [min]	Area	Height	Area%
12.602	MM m	2.99	8699.99	209.03	49.84
17.065	MM m	6.14	8755.66	54.65	50.16




RT [min]	Type	Width [min]	Area	Height	Area%
13.091	MB m	1.25	679.15	20.61	4.29
16.123	MB m	6.51	15168.50	104.29	95.71




(*R*)-methyl 1-((tert-butoxycarbonyl)(methyl)amino)-5-(3-fluorophenyl)-2-methyl-1H-pyrrole-3-carboxylate (3k)

Colorless oil. $[\alpha]_D^{25} = -76.6$ (*c* 0.62, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 1.36 (s, 6H), 1.54 (s, 3H), 2.45 (s, 3H), 3.07 (d, *J* = 47.7, 3H), 3.72-4.04 (m, 3H), 6.66 (d, *J* = 2.2, 1H), 6.93-7.22 (m, 3H), 7.34 (q, *J* = 7.2, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 165.5, 161.8, 154.0, 137.6, 133.2, 130.7, 130.4, 130.3, 130.2, 130.1, 123.7, 123.6, 122.9, 122.9, 114.7, 114.7, 114.6, 114.5, 114.5, 114.4, 114.2, 111.0, 110.8, 108.7, 108.3, 82.9, 82.6,


51.2, 51.2, 38.7, 37.6, 28.3, 28.1, 10.5, 10.5. HRMS (ESI) calcd for C₁₉H₂₃FN₂O₄ *m/z* [M+H]⁺: 363.1715, found: 359.1724. Enantiomeric excess was found to be 92% by chiral HPLC (ChiralPak OD column, hexane/*i*-PrOH = 95:5, 1.0 ml/min, *t*_{major} = 6.2 min, *t*_{minor} = 5.7 min).



RT [min]	Type	Width [min]	Area	Height	Area%
5.691	MM m	0.59	10351.73	941.10	50.03
6.276	MM m	0.93	10340.43	629.87	49.97




RT [min]	Type	Width [min]	Area	Height	Area%
5.706	MM m	0.47	425.50	39.09	3.98
6.283	MM m	1.24	10254.35	589.90	96.02




(*R*)-methyl 1-((*tert*-butoxycarbonyl)(methyl)amino)-5-(3-chlorophenyl)-2-methyl-1H-pyrrole-3-carboxylate (3l)

Colorless oil. $[\alpha]_D^{25} = -71.9$ (*c* 0.23, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 1.35 (s, 6H), 1.53 (s, 3H), 2.43 (s, 3H), 3.03 (d, *J* = 40.2, 3H), 3.80 (d, *J* = 9.0, 3H), 6.62 (d, *J* = 2.0, 1H), 7.18-7.30 (m, 3H), 7.35 (d, *J* = 3.0, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 165.5, 154.0, 137.6, 134.7, 132.9, 130.6, 130.1, 129.9, 127.7, 127.6, 126.1, 125.4, 110.8, 108.8, 108.4, 82.9, 82.7, 51.2, 51.1, 38.8, 37.6, 28.3, 28.2, 10.5, 10.5. HRMS (ESI) calcd for C₁₉H₂₃ClN₂O₄ *m/z* [M+H]⁺: 379.1419, found: 379.1414. Enantiomeric excess was


found to be 94% by chiral HPLC (ChiralPak OD column, hexane/*i*-PrOH = 99:1, 1.0 ml/min, $t_{\text{major}} = 13.5$ min, $t_{\text{minor}} = 11.5$ min).



11.480	MM m	1.89	8590.62	274.38	49.99
13.569	MM m	2.63	8595.10	159.29	50.01




RT [min]	Type	Width [min]	Area	Height	Area%
11.693	MM m	1.37	330.79	11.27	2.91
13.438	BB	5.19	11050.30	187.45	97.09




(R)-methyl 5-(3-bromophenyl)-1-((tert-butoxycarbonyl)(methyl)amino)-2-methyl-1H-pyrrole-3-carboxylate (3m)

Yellow oil. $[\alpha]_D^{25} = -58.9$ (*c* 0.92, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 1.38 (s, 6H), 2.45 (s, 3H), 3.05 (d, *J* = 37.9, 3H), 3.82 (d, *J* = 8.8, 3H), 6.64 (s, 1H), 7.22-7.33 (m, 2H), 7.44 (d, *J* = 7.8, 1H), 7.53 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 165.5, 154.0, 137.6, 133.1, 130.6, 130.6, 130.5, 130.4, 130.3, 130.2, 126.6, 125.8, 122.8, 110.8, 108.8, 108.4, 82.9, 82.7, 51.2, 51.1, 38.8, 37.6, 28.3, 28.2, 10.5, 10.5. HRMS (ESI) calcd for C₁₉H₂₃BrN₂O₄ *m/z* [M+H]⁺: 423.0914, found: 423.0921. Enantiomeric excess was


found to be 95% by chiral HPLC (ChiralPak OD column, hexane/*i*-PrOH = 98:2, 1.0 ml/min, $t_{\text{major}} = 7.3$ min, $t_{\text{minor}} = 6.6$ min).



RT [min]	Type	Width [min]	Area	Height	Area%
6.612	BM m	0.87	6818.73	478.49	50.19
7.327	MM m	1.28	6765.85	350.08	49.81




RT [min]	Type	Width [min]	Area	Height	Area%
6.641	MM m	0.41	235.55	20.41	2.46
7.243	MB m	1.73	9339.57	459.28	97.54




(*R*)-methyl 1-((tert-butoxycarbonyl)(methyl)amino)-5-(2-fluorophenyl)-2-methyl-1H-pyrrole-3-carboxylate (3n)

Colorless oil. $[\alpha]_D^{25} = -34.5$ (*c* 0.35, CHCl_3); ^1H NMR (400 MHz, CDCl_3) δ 1.39 (d, $J = 56.7$, 9H), 2.46 (s, 3H), 3.09 (d, $J = 43.0$, 3H), 3.82 (d, $J = 9.4$, 3H), 6.65 (d, $J = 13.1$, 1H), 7.13 (q, $J = 8.7$, 9.4, 2H), 7.25 (d, $J = 7.5$, 1H), 7.29-7.33 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 165.6, 161.6, 159.1, 154.1, 137.3, 131.8, 131.5, 131.5, 130.2, 130.1, 129.9, 125.7, 124.2, 124.1, 124.1, 119.2, 116.2, 116.0, 115.7, 110.6, 110.3, 109.8, 109.8, 82.5, 82.2, 51.1, 51.1, 38.8, 37.7, 37.7, 28.2, 28.1, 10.7, 10.6.. HRMS (ESI) calcd for


C₁₉H₂₃N₂O₄ m/z [M+H]⁺: 363.1715, found: 363.1707. Enantiomeric excess was found to be 92% by chiral HPLC (ChiralPak OD column, hexane/*i*-PrOH = 99:1, 1.0 ml/min, t_{major} = 19.8 min, t_{minor} = 18.6 min).



RT [min]	Type	Width [min]	Area	Height	Area%
18.622	BB	1.96	3674.34	130.71	50.03
20.481	BB	2.32	3670.33	107.05	49.97




RT [min]	Type	Width [min]	Area	Height	Area%
18.070	BB	1.80	699.35	25.48	9.91
19.813	BB	2.69	6361.20	189.42	90.09




(*R*)-methyl 1-((tert-butoxycarbonyl)(methyl)amino)-2-methyl-5-(naphthalen-1-yl)-1H-pyrrole-3-carboxylate (30)

Colorless oil. $[\alpha]_D^{25} = -50.1$ (c 0.50, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 1.38 (d, J = 18.3, 9H), 2.50 (s, 3H), 2.86 (d, J = 59.1, 3H), 3.85 (d, J = 9.6, 3H), 6.65 (dd, J = 2.8, 13.2, 1H), 7.38-7.67 (m, 4H), 7.78-8.05 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 154.0, 133.8, 133.2, 129.6, 129.2, 129.0, 128.9, 128.7, 128.3, 128.2, 126.5, 126.4, 126.1, 126.1, 125.1, 125.0, 110.2, 109.9, 82.3, 51.2, 51.1, 38.9, 38.0, 28.2, 28.1, 10.8, 10.7. HRMS


(ESI) calcd for C₂₃H₂₆N₂O₄ m/z [M+H]⁺: 395.1965, found: 395.1958. Enantiomeric excess was found to be 90% by chiral HPLC (ChiralPak OD column, hexane/*i*-PrOH = 99:1, 1.0 ml/min, t_{major} = 13.8 min, t_{minor} = 12.3 min).



RT [min]	Type	Width [min]	Area	Height	Area%
12.145	BV	2.50	11630.71	258.86	49.91
14.112	VB	4.64	11672.52	202.09	50.09




RT [min]	Type	Width [min]	Area	Height	Area%
12.347	MM m	1.07	1799.98	54.13	4.82
13.830	MB m	4.69	35569.11	634.50	95.18




(*R*)-methyl 1-((tert-butoxycarbonyl)(methyl)amino)-2-methyl-5-(naphthalen-2-yl)-1H-pyrrole-3-carboxylate (3p)

Colorless oil. $[\alpha]_D^{25} = -73.6$ (c 0.70, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 1.49 (d, J = 67.9, 9H), 2.50 (s, 3H), 3.05 (d, J = 54.6, 3H), 3.85 (d, J = 9.4, 3H), 6.75 (d, J = 10.8, 1H), 7.41-7.63 (m, 3H), 7.69-8.01 (m, 4H); ¹³C NMR (100 MHz, CDCl₃) δ 165.7, 154.3, 137.5, 133.5, 132.7, 131.8, 128.5, 128.4, 128.2, 128.2, 127.8, 127.8, 126.6, 126.5, 126.3, 126.3, 126.2, 125.8, 125.6, 110.7, 108.6, 108.2, 82.6, 82.5, 51.2, 51.1, 38.7, 37.5, 28.4,


28.2, 10.6, 10.5. HRMS (ESI) calcd for C₂₃H₂₆N₂O₄ *m/z* [M+H]⁺: 395.1965, found: 395.1961. Enantiomeric excess was found to be 90% by chiral HPLC (ChiralPak OD column, hexane/*i*-PrOH = 95:5, 1.0 ml/min, *t*_{major} = 7.6min, *t*_{minor} = 6.0 min).



RT [min]	Type	Width [min]	Area	Height	Area%
6.111	VM m	1.41	29766.50	1730.03	49.97
7.749	MM m	1.88	29796.50	865.08	50.03




RT [min]	Type	Width [min]	Area	Height	Area%
6.054	MM m	0.63	875.73	59.85	4.89
7.656	BB	2.79	17036.83	516.94	95.11




(*R*)-methyl 5-(benzo[*b*]thiophen-2-yl)-1-((tert-butoxycarbonyl)(methyl)amino)-2-methyl-1H-pyrrole-3-carboxylate (3q)

Brown oil. $[\alpha]_D^{25} = -101.1$ (*c* 0.72, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 1.33 (s, 7H), 1.57 (s, 2H), 2.46 (s, 3H), 3.26 (d, *J* = 23.3, 3H), 3.83 (d, *J* = 10.0, 3H), 6.87 (s, 1H), 7.22-7.38 (m, 3H), 7.75 (dd, *J* = 7.6, 24.0, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 165.3, 154.1, 140.0, 139.0, 137.9, 132.2, 125.7, 124.7, 124.6, 124.5, 124.4, 123.5, 123.4, 122.1, 122.1, 120.1, 119.3, 111.0, 109.2, 108.5, 82.8, 51.3, 38.9, 37.4, 28.4, 28.1, 10.5, 10.5.


HRMS (ESI) calcd for C₂₁H₂₄N₂O₄S *m/z* [M+H]⁺: 401.1530, found: 401.1522. Enantiomeric excess was found to be 90% by chiral HPLC (ChiralPak OD column, hexane/*i*-PrOH = 95:5, 1.0 ml/min, *t*_{major} = 8.2 min, *t*_{minor} = 6.2 min).



RT [min]	Type	Width [min]	Area	Height	Area%
6.220	MM m	0.92	7382.68	466.32	50.17
8.502	BB	2.80	7332.30	164.96	49.83




RT [min]	Type	Width [min]	Area	Height	Area%
6.188	MM m	0.79	611.47	41.21	4.98
8.271	BB	2.69	11668.04	273.97	95.02




(*R*)-methyl 1-((tert-butoxycarbonyl)(methyl)amino)-2-methyl-5-(thiophen-2-yl)-1H-pyrrole-3-carboxylate (3r)

Ink green oil $[\alpha]_D^{25} = -57.8$ (*c* 0.56, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 1.33 (s, 7H), 1.57 (s, 2H), 2.46 (s, 3H), 3.26 (d, *J* = 23.3, 3H), 3.83 (d, *J* = 10.0, 3H), 6.87 (s, 1H), 7.22-7.38 (m, 3H), 7.75 (dd, *J* = 7.6, 24.0, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 165.3, 154.1, 140.0, 139.0, 137.9, 132.2, 125.7, 124.7, 124.6, 124.5, 124.4, 123.5, 123.4, 122.1,


122.1, 120.1, 119.3, 111.0, 109.2, 108.5, 82.8, 51.3, 38.9, 37.4, 28.4, 28.1, 10.5, 10.5.
 HRMS (ESI) calcd for C₁₇H₂₂N₂O₄S *m/z* [M+H]⁺: 351.1373, found: 351.1375.
 Enantiomeric excess was found to be 93% by chiral HPLC (ChiralPak OD column,
 hexane/*i*-PrOH = 99:1, 1.0 ml/min, *t*_{major} = 22.2 min, *t*_{minor} = 17.2 min).



RT [min]	Type	Width [min]	Area	Height	Area%
17.220	MM m	3.07	14856.99	253.75	50.14
21.821	MM m	8.40	14773.75	88.64	49.86




RT [min]	Type	Width [min]	Area	Height	Area%
17.851	MM m	2.31	203.13	3.62	3.43
22.173	BB	9.52	5727.12	32.54	96.57




(*R*)-methyl 1-((tert-butoxycarbonyl)(methyl)amino)-5-(furan-2-yl)-2-methyl-1H-pyrrole-3-carboxylate (3s)

Yellow oil. $[\alpha]_D^{25} = -25.5$ (*c* 0.17, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 1.29 (s, 7H), 1.54 (s, 2H), 2.45 (s, 3H), 3.26 (s, 3H), 3.82 (d, *J* = 9.4, 3H), 6.36 (dd, *J* = 3.4, 51.9, 2H), 6.78 (d, *J* = 11.7, 1H), 7.39 (d, *J* = 6.8, 1H); ¹³C NMR (100 MHz, CDCl₃) 165.5, 154.3, 145.6, 141.6, 141.5, 137.4, 123.0, 111.4, 111.3, 110.5, 107.2, 106.7, 105.2, 105.1,


82.2, 51.2, 51.1, 38.6, 37.1, 28.3, 28.0, 10.3. HRMS (ESI) calcd for C₁₇H₂₂N₂O₅ *m/z* [M+H]⁺: 335.1601, found: 335.1595. Enantiomeric excess was found to be 90% by chiral HPLC (ChiralPak OD column, hexane/*i*-PrOH = 99:1, 1.0 ml/min, *t*_{major} = 16.0 min, *t*_{minor} = 11.3 min).



RT [min]	Type	Width [min]	Area	Height	Area%
10.967	MM m	3.49	12968.50	235.83	50.36
15.935	MB m	4.76	12780.80	227.25	49.64




RT [min]	Type	Width [min]	Area	Height	Area%
11.281	BM m	4.67	2738.23	47.35	95.02
16.012	MM m	1.42	143.64	3.50	4.98




(*R*)-ethyl 5-(3-bromophenyl)-1-((tert-butoxycarbonyl)(methyl)amino)-2-methyl-1H-pyrrole-3-carboxylate (3t)

Colorless oil. $[\alpha]_D^{25} = -58.5$ (*c* 0.77, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 1.47 (d, *J* = 68.1, 12H), 2.45 (s, 3H), 3.05 (d, *J* = 35.8, 3H), 4.26-4.29 (m, 2H), 6.66 (s, 1H), 7.23 (*m*, 1H), 7.27-7.35 (m, 1H), 7.44 (d, *J* = 7.9, 1H), 7.54 (s, 1H).; ¹³C NMR (100 MHz,


CDCl₃) δ 154.1, 137.5, 133.2, 130.6, 130.5, 130.4, 130.3, 130.2, 126.6, 125.8, 122.8, 111.1, 108.9, 108.5, 82.9, 82.7, 59.9, 59.8, 38.8, 37.6, 28.4, 28.2, 14.6, 14.6, 10.5, 10.5. HRMS (ESI) calcd for C₂₀H₂₅BrN₂O₄ *m/z* [M+H]⁺: 437.1070, found: 437.1060. Enantiomeric excess was found to be 96% by chiral HPLC (ChiralPak OD column, hexane/*i*-PrOH = 95:5, 1.0 ml/min, *t*_{major} = 6.2 min, *t*_{minor} = 5.4 min).



RT [min]	Type	Width [min]	Area	Height	Area%
5.463	MM m	0.60	43476.02	3092.36	49.99
6.046	MM m	0.92	43493.45	2923.83	50.01




RT [min]	Type	Width [min]	Area	Height	Area%
5.473	MM m	0.91	11038.84	747.96	97.59
6.231	MM m	0.56	272.66	22.10	2.41




(*R*)-tert-butyl 5-(3-bromophenyl)-1-((tert-butoxycarbonyl)(methyl)amino)-2-methyl-1H-pyrrole-3-carboxylate (3u)

Colorless oil. $[\alpha]_D^{25} = -61.3$ (*c* 0.66, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 1.36-1.60 (m, 18H), 2.42 (s, 3H), 3.04 (d, *J* = 31.9, 3H), 6.60 (d, *J* = 5.0, 1H), 7.11-7.25 (m, 1H), 7.27-7.33 (m, 1H), 7.43 (d, *J* = 7.8, 1H), 7.53 (d, *J* = 2.2, 1H); ¹³C NMR (100 MHz,


CDCl₃) δ 164.5, 154.1, 136.9, 133.3, 130.6, 130.5, 130.5, 130.3, 130.1, 130.1, 130.0, 126.6, 125.8, 122.8, 112.6, 109.1, 108.7, 82.8, 82.7, 80.1, 79.9, 38.8, 37.6, 28.6, 28.6, 28.4, 28.2, 10.5. HRMS (ESI) calcd for C₂₂H₂₉BrN₂O₄ *m/z* [M+H]⁺: 465.1383, found: 465.1393. Enantiomeric excess was found to be 96% by chiral HPLC (ChiralPak OD column, hexane/*i*-PrOH = 95:5, 1.0 ml/min, *t*_{major} = 9.1 min, *t*_{minor} = 5.2 min).



RT [min]	Type	Width [min]	Area	Height	Area%
5.165	MM m	0.83	34444.48	2203.26	50.09
8.966	MM m	4.88	34313.97	584.72	49.91




RT [min]	Type	Width [min]	Area	Height	Area%
5.189	BB	1.91	6958.47	438.49	98.03
9.115	MM m	2.53	139.63	2.29	1.97




(*R*)-benzyl 5-(3-bromophenyl)-1-((tert-butoxycarbonyl)(methyl)amino)-2-methyl-1H-pyrrole-3-carboxylate (3v)

Colorless oil. $[\alpha]_D^{25} = -59.1$ (*c* 0.54, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 1.47 (d, *J* = 67.0, 9H), 2.46 (s, 3H), 3.05 (d, *J* = 35.5, 3H), 5.30 (d, *J* = 5.4, 2H), 6.69 (t, *J* = 2.5, 1H), 7.22-7.50 (m, 8H), 7.53 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 164.8, 154.0, 137.9, 133.1, 130.7, 130.6, 130.5, 130.5, 130.4, 130.3, 130.2, 128.7, 128.6, 128.2, 128.2,


128.1, 128.1, 126.6, 125.8, 122.8, 110.8, 109.0, 108.6, 82.9, 82.7, 65.7, 65.6, 38.8, 37.6, 28.3, 28.2, 10.6, 10.6. HRMS (ESI) calcd for C₂₅H₂₇BrN₂O₄ *m/z* [M+H]⁺: 499.1227, found: 499.1220. Enantiomeric excess was found to be 95% by chiral HPLC (ChiralPak OD column, hexane/*i*-PrOH = 95:5, 1.0 ml/min, *t*_{major} = 9.1 min, *t*_{minor} = 5.2 min).



RT [min]	Type	Width [min]	Area	Height	Area%
7.725	BM m	1.33	737.86	32.19	49.97
9.008	MB m	2.42	738.78	27.30	50.03




RT [min]	Type	Width [min]	Area	Height	Area%
7.581	BB	1.61	5312.60	249.89	97.52
9.089	MM m	0.84	135.36	6.05	2.48




(*R*)-methyl 5-(3-bromophenyl)-1-((tert-butoxycarbonyl)(methyl)amino)-2-ethyl-1H-pyrrole-3-carboxylate (3w)

Colorless oil. $[\alpha]_D^{25} = -64.1$ (*c* 0.41, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 1.24 (t, *J* = 7.4, 3H), 1.36 (s, 6H), 1.55 (s, 3H), 2.84-2.90 (m, 2H), 3.01 (s, 1H), 3.15 (s, 2H), 3.82 (d, *J* = 8.1, 3H), 6.65 (d, *J* = 4.4, 1H), 7.17-7.25 (m, 1H), 7.27-7.38 (m, 1H), 7.44 (dd, *J* = 2.0, 7.6, 1H), 7.54 (dd, *J* = 1.9, 8.5, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 165.1,


154.1, 143.6, 133.3, 130.9, 130.7, 130.7, 130.7, 130.5, 130.3, 130.1, 126.9, 126.0, 122.8, 110.3, 109.2, 108.8, 82.8, 51.2, 51.1, 39.4, 38.5, 28.3, 28.1, 18.6, 18.4, 13.8, 13.5. HRMS (ESI) calcd for C₂₀H₂₅BrN₂O₄ *m/z* [M+H]⁺: 437.1070, found: 437.1064. Enantiomeric excess was found to be 86% by chiral HPLC (ChiralPak OD column, hexane/*i*-PrOH = 95:5, 1.0 ml/min, *t*_{major} = 7.7 min, *t*_{minor} = 6.2 min).



RT [min]	Type	Width [min]	Area	Height	Area%
5.959	BV	1.24	28452.65	1029.94	49.66
7.389	VBA	4.91	28840.10	422.18	50.34




RT [min]	Type	Width [min]	Area	Height	Area%
6.245	MM m	1.10	234.82	8.60	6.98
7.749	MB m	5.80	3127.66	47.24	93.02




(*R*)-methyl 5-(3-bromophenyl)-1-((tert-butoxycarbonyl)(ethyl)amino)-2-methyl-1H-pyrrole-3-carboxylate (3x)

Colorless oil. $[\alpha]_D^{25} = -74.1$ (*c* 0.35, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 0.78-0.81 (m, 3H), 1.47 (d, *J* = 2.3, 5H), 1.59 (s, 4H), 2.44 (s, 3H), 3.21-3.70 (m, 2H), 3.74-4.08 (m, 3H), 6.65 (d, *J* = 2.6, 1H), 7.25-7.27 (m, 2H), 7.43 (d, *J* = 7.9, 1H), 7.53 (s, 1H); ¹³C


NMR (100 MHz, CDCl₃) δ 165.5, 154.1, 138.6, 138.5, 133.5, 130.9, 130.6, 130.3, 130.1, 126.9, 126.1, 122.8, 108.8, 108.6, 82.8, 82.7, 51.2, 51.1, 46.9, 45.3, 28.4, 28.4, 12.7, 12.2, 11.0, 10.9. HRMS (ESI) calcd for C₂₀H₂₅BrN₂O₄ m/z [M+H]⁺: 437.1070, found: 437.1063. Enantiomeric excess was found to be 86% by chiral HPLC (ChiralPak OD column, hexane/*i*-PrOH = 99:1, 1.0 ml/min, t_{major} = 11.2 min, t_{minor} = 9.6 min).



RT [min]	Type	Width [min]	Area	Height	Area%
9.549	MM m	1.98	3975.67	92.82	49.88
11.346	MM m	3.32	3995.45	107.25	50.12




RT [min]	Type	Width [min]	Area	Height	Area%
9.678	MM m	1.41	214.08	5.11	4.99
11.222	MM m	3.18	4079.50	105.27	95.01




(*R*)-methyl 5-(3-bromophenyl)-1-((*tert*-butoxycarbonyl)(propyl)amino)-2-methyl-1H-pyrrole-3-carboxylate (3y)

Colorless oil. $[\alpha]_D^{25} = -62.2$ (c 0.39, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ = 0.68 (q, J = 6.7, 3H), 1.22-1.25 (m, 2H), 1.48 (s, 5H), 1.59 (s, 4H), 2.44 (s, 3H), 3.10-3.45 (m, 2H), 3.82 (d, J = 8.8, 3H), 6.64 (d, J = 2.7, 1H), 7.23 (d, J = 6.5, 1H), 7.30 (t, J = 8.0,


1H), 7.44 (d, $J = 7.9$, 1H), 7.54 (s, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 154.3, 138.3, 133.4, 131.0, 130.9, 130.7, 130.6, 130.3, 130.1, 126.9, 126.2, 122.8, 110.6, 108.8, 108.6, 82.8, 82.7, 54.0, 52.5, 51.2, 51.1, 28.4, 28.4, 21.0, 20.5, 11.2, 11.1, 11.0, 10.9. HRMS (ESI) calcd for $\text{C}_{21}\text{H}_{27}\text{BrN}_2\text{O}_4$ m/z $[\text{M}+\text{H}]^+$: 451.1227, found: 451.1219. Enantiomeric excess was found to be 90% by chiral HPLC (ChiralPak OD column, hexane/*i*-PrOH = 99:1, 1.0 ml/min, $t_{\text{major}} = 10.4$ min, $t_{\text{minor}} = 8.0$ min).



RT [min]	Type	Width [min]	Area	Height	Area%
7.871	BM m	2.25	12656.65	390.26	49.75
10.056	MM m	2.35	12785.87	407.30	50.25




RT [min]	Type	Width [min]	Area	Height	Area%
8.068	MM m	1.31	132.40	3.71	4.88
10.452	BB	3.13	2578.41	78.65	95.12




(*R*)-methyl 1-(allyl(tert-butoxycarbonyl)amino)-5-(3-bromophenyl)-2-methyl-1H-pyrrole-3-carboxylate (3z)

Yellow oil. $[\alpha]_D^{25} = -36.5$ (c 0.5, CHCl_3); ^1H NMR (400 MHz, CDCl_3) δ 0.13-0.35 (m, 1H), 0.35-0.49 (m, 1H), 0.57 (d, $J = 15.8$, 2H), 1.47 (s, 5H), 1.59 (s, 4H), 2.41 (s, 3H), 2.76 (d, $J = 53.1$, 1H), 3.82 (d, $J = 6.4$, 3H), 6.62 (s, 1H), 7.22 (d, $J = 7.9$, 1H), 7.28 (s,


1H), 7.43-7.45 (m, 1H), 7.51 (d, $J = 2.7$, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 165.6, 154.7, 137.8, 131.2, 131.0, 130.8, 130.7, 130.6, 130.3, 126.9, 126.3, 122.7, 110.5, 108.3, 83.1, 82.9, 51.2, 33.1, 32.8, 28.3, 10.7, 7.7, 6.9, 6.7. HRMS (ESI) calcd for $\text{C}_{21}\text{H}_{26}\text{BrN}_2\text{O}_4$ m/z $[\text{M}+\text{H}]^+$: 449.1071, found: 449.1078. Enantiomeric excess was found to be 80% by chiral HPLC (ChiralPak OD column, hexane/*i*-PrOH = 99:1, 1.0 ml/min, $t_{\text{major}} = 9.3$ min, $t_{\text{minor}} = 8.8$ min).



RT [min]	Type	Width [min]	Area	Height	Area%
8.824	BV	0.54	3882.33	311.50	49.19
9.365	VB	0.79	4010.49	288.69	50.81




RT [min]	Type	Width [min]	Area	Height	Area%
8.828	MM m	0.35	271.69	26.17	9.95
9.351	MM m	0.77	2457.59	172.40	90.05




(*S*)-methyl 5-(3-bromophenyl)-1-((tert-butoxycarbonyl)(phenyl)amino)-2-methyl-1H-pyrrole-3-carboxylate (3aa)

Colorless oil. $[\alpha]_D^{25} = -0.49$ (c 0.41, CHCl_3); ^1H NMR (400 MHz, CDCl_3) δ 1.33 (s, 9H), 2.35 (d, $J = 40.6$, 6H), 3.85 (s, 3H), 6.71 (s, 1H), 7.04-7.31 (m, 9H); ^{13}C NMR (100


MHz, CDCl₃) δ 165.2, 153.9, 138.5, 137.0, 136.4, 131.4, 131.4, 129.3, 129.1, 129.0, 128.3, 128.2, 127.6, 127.5, 126.5, 124.4, 91.5, 84.5, 82.7, 51.3, 51.2, 38.6, 37.5, 28.3, 28.2, 21.6, 21.5, 10.8, 10.7. HRMS (ESI) calcd for C₂₅H₂₈N₂O₄ *m/z* [M+H]⁺: 421.2122, found: 421.2126. Enantiomeric excess was found to be 90% by chiral HPLC (ChiralPak IC column, hexane/*i*-PrOH = 95:5, 1.0 ml/min, *t*_{major} = 7.0 min, *t*_{minor} = 8.6 min).



RT [min]	Type	Width [min]	Area	Height	Area%
7.024	VB	1.54	11654.84	810.59	50.01
8.615	BB	1.41	11650.81	701.88	49.99




RT [min]	Type	Width [min]	Area	Height	Area%
7.069	VM m	1.56	11431.74	803.48	95.00
8.665	MM m	0.55	601.52	39.91	5.00




(S)-methyl 1-(benzyl(tert-butoxycarbonyl)amino)-2-methyl-5-(p-tolyl)-1H-pyrrole-3-carboxylate (3ab)

Colorless oil. $[\alpha]_D^{25} = -12.8$ (*c* 1.0, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 1.56 (t, *J* = 2.0, 6H), 1.71 (s, 3H), 1.95 (dt, *J* = 2.0, 14.6, 3H), 2.47 (d, *J* = 3.1, 3H), 3.77-3.90 (m, 3H), 3.95 (t, *J* = 13.4, 1H), 4.92 (dd, *J* = 14.6, 89.8, 1H), 6.67 (d, *J* = 3.0, 1H), 7.01 (dd, *J* =


7.4, 24.5, 2H), 7.18-7.39 (m, 8H); ^{13}C NMR (100 MHz, CDCl_3) δ 165.8, 154.2, 138.5, 137.6, 134.6, 131.4, 129.9, 129.6, 129.5, 129.4, 128.6, 128.6, 128.5, 128.4, 128.4, 128.1, 127.5, 109.8, 108.0, 107.7, 82.9, 82.6, 55.3, 53.4, 51.0, 51.0, 28.5, 28.4, 21.3, 10.5. HRMS (ESI) calcd for $\text{C}_{26}\text{H}_{30}\text{N}_2\text{O}_4$ m/z $[\text{M}+\text{H}]^+$: 435.2278, found: 435.2273. Enantiomeric excess was found to be 80% by chiral HPLC (ChiralPak IC column, hexane/*i*-PrOH = 96:4, 1.0 ml/min, $t_{\text{major}} = 5.6$ min, $t_{\text{minor}} = 5.0$ min).



RT [min]	Type	Width [min]	Area	Height	Area%
5.089	MM m	0.53	3254.66	253.62	50.18
5.678	MM m	0.92	3230.70	181.76	49.82




RT [min]	Type	Width [min]	Area	Height	Area%
5.096	MM m	0.55	250.28	24.88	9.94
5.668	MM m	1.71	2268.84	117.41	90.06




(S)-methyl 1-((tert-butoxycarbonyl)(thiophen-2-yl)amino)-2-methyl-5-(p-tolyl)-1H-pyrrole-3-carboxylate (3ac)

Yellow oil. $[\alpha]_D^{25} = -28.6$ (c 0.29, CHCl_3); ^1H NMR (400 MHz, CDCl_3) δ 1.28 (s, 9H), 2.35 (d, $J = 39.2$, 6H), 3.85 (s, 3H), 6.06 (s, 1H), 6.73 (d, $J = 17.8$, 2H), 6.91 (d, $J = 5.2$,


1H), 7.01-7.23 (m, 4H); ¹³C NMR (100 MHz, CDCl₃) δ 165.6, 151.1, 142.7, 137.7, 137.0, 132.8, 129.5, 127.7, 127.3, 124.6, 119.5, 112.4, 111.2, 107.5, 84.3, 51.2, 27.9, 21.3, 10.5. HRMS (ESI) calcd for C₂₃H₂₆N₂O₄S *m/z* [M+H]⁺: 427.1686, found: 427.1684. Enantiomeric excess was found to be 88% by chiral HPLC (ChiralPak IC column, hexane/*i*-PrOH = 95:5, 1.0 ml/min, *t*_{major} = 5.7 min, *t*_{minor} = 4.7 min).



RT [min]	Type	Width [min]	Area	Height	Area%
4.751	BB	1.00	40919.68	3273.76	50.00
5.732	BM m	1.14	40922.49	2063.71	50.00




RT [min]	Type	Width [min]	Area	Height	Area%
4.742	MM m	0.42	934.45	88.94	5.90
5.757	MM m	1.29	14890.73	779.37	94.10




(*R*)-methyl 1-((tert-butoxycarbonyl)(methyl)amino)-4-iodo-2-methyl-5-(*p*-tolyl)-1H-pyrrole-3-carboxylate (4)

Yellow solid. [α]_D²⁵ = -59.3 (*c* 0.46, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 1.46 (d, *J* = 29.5, 9H), 2.43 (d, *J* = 10.5, 6H), 2.94 (d, *J* = 34.4, 3H), 3.88 (d, *J* = 9.4, 3H), 7.16-7.31


(m, 4H); ^{13}C NMR (100 MHz, CDCl_3) δ 164.5, 153.7, 139.0, 138.8, 137.6, 135.8, 130.7, 130.5, 129.2, 129.1, 127.9, 112.0, 82.6, 82.5, 63.1, 51.0, 51.0, 38.7, 37.7, 28.2, 28.2, 21.6, 21.5, 11.6, 11.5. HRMS (ESI) calcd for $\text{C}_{20}\text{H}_{25}\text{N}_2\text{O}_4$ m/z $[\text{M}+\text{H}]^+$: 485.0932, found: 485.0929. Enantiomeric excess was found to be 93% by chiral HPLC (ChiralPak IF column, hexane/*i*-PrOH = 99:1, 0.5 ml/min, t_{major} = 37.4 min, t_{minor} = 32.2 min).



RT [min]	Type	Width [min]	Area	Height	Area%
31.872	MB m	4.46	4731.26	40.68	50.03
36.763	BM m	6.69	4725.30	33.62	49.97




RT [min]	Type	Width [min]	Area	Height	Area%
32.242	BB	6.36	20183.34	160.42	96.64
37.453	MM m	5.06	702.51	5.36	3.36




(*R*)-methyl 1-((tert-butoxycarbonyl)(methyl)amino)-2-formyl-5-(*p*-tolyl)-1H-pyrrole-3-carboxylate (5)

Colorless oil. $[\alpha]_D^{25} = -42.9$ (c 0.72, CHCl_3); ^1H NMR (400 MHz, CDCl_3) δ 1.32 (s, 6H), 1.54 (s, 3H), 2.40 (s, 3H), 3.07 (d, $J = 15.0$, 3H), 3.91 (d, $J = 10.4$, 3H), 6.76 (t, $J = 2.8$,


1H), 7.24 (d, $J = 7.9$, 2H), 7.36 (dd, $J = 2.9$, 8.0, 2H), 10.23-10.60 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 181.0, 180.7, 154.1, 139.8, 139.6, 129.6, 129.5, 129.4, 128.6, 128.3, 126.2, 126.1, 123.1, 110.2, 109.9, 82.8, 82.3, 52.2, 52.1, 39.2, 37.8, 28.3, 28.1, 21.5, 21.5. HRMS (ESI) calcd for $\text{C}_{20}\text{H}_{24}\text{N}_2\text{O}_5$ m/z $[\text{M}+\text{H}]^+$: 373.1758, found: 373.1755. Enantiomeric excess was found to be 90% by chiral HPLC (ChiralPak AD column, hexane/*i*-PrOH = 99:1, 1 ml/min, $t_{\text{major}} = 47.2$ min, $t_{\text{minor}} = 27.8$ min).



RT [min]	Type	Width [min]	Area	Height	Area%
27.240	MM m	15.46	26572.97	67.54	50.15
49.417	MM m	45.15	26409.19	22.74	49.85




RT [min]	Type	Width [min]	Area	Height	Area%
27.789	MM m	9.36	1527.40	4.99	4.90
47.191	MM m	52.35	29632.03	29.59	95.10




(R)- 1-((tert-butoxycarbonyl)(methyl)amino)-2-methyl-5-(p-tolyl)-1H-pyrrole-3-carboxylic acid (6)

Colorless oil. $[\alpha]_D^{25} = -63.8$ (c 0.27, CHCl_3); ^1H NMR (400 MHz, CDCl_3) δ 1.46 (d, $J =$


73.3, 9H), 2.43 (d, $J = 40.1$, 6H), 3.05 (d, $J = 51.9$, 3H), 6.66 (s, 1H), 7.14-7.27 (m, 4H); ^{13}C NMR (100 MHz, CDCl_3) δ 170.4, 170.2, 154.2, 138.4, 138.2, 137.7, 132.4, 129.5, 129.4, 128.2, 128.1, 127.5, 109.8, 108.2, 107.8, 82.6, 82.4, 38.7, 37.5, 28.3, 28.2, 21.4, 21.3, 10.7, 10.7. HRMS (ESI) calcd for $\text{C}_{19}\text{H}_{24}\text{N}_2\text{O}_4$ m/z $[\text{M}+\text{H}]^+$: 345.1809, found: 345.1817. Enantiomeric excess was found to be 92% by chiral HPLC (ChiralPak IC column, hexane/*i*-PrOH = 80:20, 0.7 ml/min, $t_{\text{major}} = 34.1$ min, $t_{\text{minor}} = 16.3$ min).



RT [min]	Type	Width [min]	Area	Height	Area%
16.344	MM m	16.41	10772.49	64.03	49.98
34.126	MM m	29.02	10781.39	18.25	50.02




RT [min]	Type	Width [min]	Area	Height	Area%
16.241	VM m	18.70	207020.97	1713.93	95.92
34.373	MM m	33.58	8800.91	21.72	4.08




(R)-methyl 1-((tert-butoxycarbonyl)(methyl)amino)-2-methyl-4-phenyl-5-(p-tolyl)-1H-pyrrole-3-carboxylate (7)

Yellow oil. $[\alpha]_D^{25} = -91.6$ (c 0.31, CHCl_3); ^1H NMR (400 MHz, CDCl_3) δ 1.47 (d, $J =$


42.9, 9H), 2.37 (d, $J = 73.4$, 6H), 2.98 (d, $J = 47.7$, 3H), 3.62 (d, $J = 11.9$, 3H), 7.00 (d, $J = 11.1$, 4H), 7.16 (d, $J = 11.0$, 5H); ^{13}C NMR (100 MHz, CDCl_3) δ 166.1, 154.2, 137.6, 137.4, 136.0, 135.3, 130.9, 130.8, 130.5, 130.4, 130.3, 129.0, 128.9, 127.4, 127.3, 126.1, 126.0, 122.2, 82.4, 82.2, 50.8, 50.7, 38.8, 37.7, 28.3, 28.3, 21.4, 21.4, 11.0, 10.9. HRMS (ESI) calcd for $\text{C}_{26}\text{H}_{30}\text{N}_2\text{O}_4$ m/z $[\text{M}+\text{H}]^+$: 435.2278, found: 435.2269. Enantiomeric excess was found to be 92% by chiral HPLC (ChiralPak IF column, hexane/*i*-PrOH = 99:1, 1 ml/min, $t_{\text{major}} = 13.4$ min, $t_{\text{minor}} = 16.8$ min).



RT [min]	Type	Width [min]	Area	Height	Area%
14.016	MM m	2.57	4416.07	83.34	49.44
17.386	MM m	3.99	4516.13	44.12	50.56




RT [min]	Type	Width [min]	Area	Height	Area%
13.427	MM m	3.13	13996.05	280.45	96.11
16.781	MM m	3.30	566.00	6.22	3.89




(*R*)-methyl 1-((tert-butoxycarbonyl)(methyl)amino)-2-methyl-4-(phenylethynyl)-5-(*p*-tolyl)-1H-pyrrole-3-carboxylate (8)


Colorless oil. $[\alpha]_D^{25} = -69.5$ (c 0.37, CHCl_3); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 1.47 (d, $J = 60.1$, 9H), 2.43 (d, $J = 23.3$, 6H), 2.97 (d, $J = 48.7$, 3H), 3.91 (d, $J = 10.1$, 3H), 7.26 (q, $J = 6.4, 7.4$, 6H), 7.33-7.50 (m, 4H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 165.7, 152.0, 141.1, 137.5, 137.3, 133.0, 129.4, 129.0, 128.1, 127.4, 124.9, 110.8, 107.5, 83.4, 51.2, 28.0, 21.3, 10.8. HRMS (ESI) calcd for $\text{C}_{28}\text{H}_{30}\text{N}_2\text{O}_4$ m/z $[\text{M}+\text{H}]^+$: 459.2278, found: 459.2282. Enantiomeric excess was found to be 91% by chiral HPLC (ChiralPak IC column, hexane/*i*-PrOH = 96:4, 1 ml/min, $t_{\text{major}} = 21.5$ min, $t_{\text{minor}} = 16.5$ min).



RT [min]	Type	Width [min]	Area	Height	Area%
15.225	MM m	4.34	738.34	7.84	50.81
19.953	MM m	6.30	714.70	4.51	49.19




RT [min]	Type	Width [min]	Area	Height	Area%
16.500	MM m	3.36	1009.79	9.05	4.72
21.534	BB	9.70	20379.68	100.37	95.28




(R)-methyl 1-((tert-butoxycarbonyl)(methyl)amino)-2-methyl-4-(prop-1-en-2-yl)-5-(p-tolyl)-1H-pyrrole-3-carboxylate (9)

Colorless oil. $[\alpha]_D^{25} = -55.2$ (c 0.72, CHCl_3); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 1.43 (d, $J = 37.7$, 9H), 1.95 (s, 3H), 2.37 (d, $J = 16.7$, 6H), 2.94 (d, $J = 43.5$, 3H), 3.79 (dd, $J = 2.6$, 11.0, 3H), 4.67 (d, $J = 9.6$, 1H), 4.96 (s, 1H), 7.09-7.22 (m, 4H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 154.2, 139.7, 137.9, 137.7, 135.7, 130.3, 130.1, 129.0, 128.8, 127.8, 127.8, 115.9, 115.8, 82.3, 51.0, 50.9, 38.8, 37.7, 28.2, 25.0, 24.9, 21.5, 21.5, 10.9, 10.9. HRMS (ESI) calcd for $\text{C}_{23}\text{H}_{31}\text{N}_2\text{O}_4$ m/z $[\text{M}+\text{H}]^+$: 399.2278, found: 399.2283. Enantiomeric excess was found to be 90% by chiral HPLC (ChiralPak IC column, hexane/*i*-PrOH = 99:1, 1 ml/min, $t_{\text{major}} = 18.4$ min, $t_{\text{minor}} = 25.0$ min).



RT [min]	Type	Width [min]	Area	Height	Area%
18.028	BB	3.11	9212.05	185.14	49.76
24.221	BB	5.67	9302.04	87.37	50.24



RT [min]	Type	Width [min]	Area	Height	Area%
18.383	BM m	5.91	27922.78	484.49	95.00
25.026	MM m	4.90	1468.15	10.18	5.00

(J) References

- [1] Matheson, C. J.; Casalvieri, K. A.; Backos, D. S.; et al. Development of Potent Pyrazolopyrimidinone-Based WEE1 Inhibitors with Limited Single-Agent Cytotoxicity for Cancer Therapy. *ChemMedChem*, **2018**, *13*, 1681–1694.
- [2] Strick, B. F.; Mundal, D. A.; Thomson, R. J. An oxidative [2, 3]-sigmatropic rearrangement of allylic hydrazides. *J. Am. Chem. Soc.* **2011**, *133*, 14252–14255.
- [3] Wei, Y.; Sun, F.; Li, G.; et al. Enantioselective synthesis of N–N amide–pyrrole atropisomers via Paal–Knorr reaction. *Org. Lett.* **2023**, *26*, 2343–2348.
- [4] Lin, J. S.; Li, T. T.; Liu, J. R.; et al. Cu/chiral phosphoric acid-catalyzed asymmetric three-component radical-initiated 1, 2-dicarbofunctionalization of alkenes. *J. Am. Chem. Soc.* **2018**, *141*, 1074–1083.

(K) NMR Spectra

